Focused On-demand Library for Homeobox protein Meis1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
O00470

UPID:
MEIS1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
O00470; A8MV50

BACKGROUND:
The Homeobox protein Meis1, with its crucial functions in transcriptional regulation, hematopoiesis, and vascular development, is a key player in cellular differentiation and disease. Its ability to activate PF4 and regulate PAX6, alongside its role in megakaryocyte and vascular patterning, underscores its biological significance.

THERAPEUTIC SIGNIFICANCE:
Given its association with Restless legs syndrome 7, characterized by nocturnal insomnia and chronic sleep deprivation, Homeobox protein Meis1 presents a promising avenue for research into disease mechanisms and therapeutic solutions. Its role in disease susceptibility suggests potential for targeted therapy development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 789 of 8789